Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 14, 2016 - Issue 8
Submit an article Journal homepage
146
Views
0
CrossRef citations to date
0
Altmetric
Drug Profile

Reversal of Dabigatran with Idarucizumab

Neel R. SodhaDivision of Cardiac Surgery, Alpert Medical School, Brown University, Providence, RI, USA
&
Frank W. SellkeDivision of Cardiac Surgery, Alpert Medical School, Brown University, Providence, RI, USACorrespondence[email protected]
Pages 889-893 | Received 05 Mar 2016, Accepted 15 Jun 2016, Published online: 30 Jun 2016

References

  • Mueller RL, Scheidt S History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation. Jan 1994;89(1): 432–449.
  • Bauer KA Targeted anti-anticoagulants. N Engl J Med. Aug 6 2015;373(6):569–571.
  • Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. Sep 17 2009;361(12): 1139–1151.
  • Eikelboom JW, Quinlan DJ, van Ryn J, et al. Idarucizumab: the antidote for reversal of dabigatran. Circulation. Dec 22 2015;132(25):2412–2422.
  • Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. Dec 10 2009;361(24):2342–2352.
  • Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. Feb 21 2013;368(8): 709–718.
  • Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. May 2013;15(5):625–651.
  • Crowther M, Crowther MA Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol. Aug 2015;35(8):1736–1745.
  • Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. Apr 2010;49(4):259–268.
  • Singh T, Maw TT, Henry BL, et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol Sep 2013;8(9): 1533–1539.
  • Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. May 2 2013;121(18):3554–3562.
  • Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. May 2015;113(5):943–951.
  • Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. Aug 15 2015;386(9994): 680–690.
  • Burness CB Idarucizumab: first global approval. Drugs. Dec 2015;75(18):2155–2161.
  • Glund SSJ, Schmohl M, Moschetti V, et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood. 2014;124:344.
  • Na SY, Mracsko E, van Ryn J, et al. Idarucizumab improves outcome in murine brain hemorrhage related to dabigatran. Ann Neurol. Jul 2015;78(1):137–141.
  • Grottke O, Honickel M, van Ryn J, et al. Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation. J Am Coll Cardiol. Sep 29 2015;66(13): 1518–1519.
  • Pollack CV Jr, Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. Jul 2015;114(1):198–205.
  • Pollack CV Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. Aug 6 2015;373(6): 511–520.
  • Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. Nov 27 2014;371(22): 2141–2142.
  • Costin J, Ansell J, Laulicht B, et al. Reversal agents in development for the new oral anticoagulants. Postgrad Med. Nov 2014;126(7):19–24.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.